[A21-113] Icosapent ethyl (hypertriglyceridaemia) - Benefit assessment according to §35a Social Code Book V
Last updated 18.02.2022
Project no.:
A21-113
Commission:
Commission awarded on 01.09.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Digestion, metabolism and hormones
Reduction of the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (≥ 150 mg/dL [≥ 1.7 mmol/L]) and
- Established cardiovascular disease or
- diabetes mellitus and at least one further cardiovascular risk factor
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A22-03 | Icosapent ethyl (cardiovascular risk reduction) - Addendum to Commission A21-113 | Commission completed |
Federal Joint Committee (G-BA)
2022-02-18G-BA documents on this decision
A G-BA decision was published.